(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 14.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Amicus Therapeutics's revenue in 2025 is $598,704,000.On average, 12 Wall Street analysts forecast FOLD's revenue for 2025 to be $198,016,831,106, with the lowest FOLD revenue forecast at $188,464,632,460, and the highest FOLD revenue forecast at $205,878,265,909. On average, 12 Wall Street analysts forecast FOLD's revenue for 2026 to be $234,161,536,255, with the lowest FOLD revenue forecast at $221,690,610,244, and the highest FOLD revenue forecast at $244,984,893,118.
In 2027, FOLD is forecast to generate $277,124,832,814 in revenue, with the lowest revenue forecast at $255,798,993,976 and the highest revenue forecast at $295,516,517,610.